MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain

Gene Therapy

Volumn 24, Issue 4, 2017, Pages 253-261

  Samaranch, L ^a   Blits, B ^b   San Sebastian, W ^a   Hadaczek, P ^a   Bringas, J ^a   Sudhakar, V ^a   Macayan, M ^a   Pivirotto, P J ^a   Petry, H ^b   Bankiewicz, K S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIQURE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; GREEN FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; HUMAN ADENOVIRUS 5; MACACA FASCICULARIS; MALE; NERVE CELL; NERVE FIBER TRANSPORT; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; ANIMAL; BRAIN; DEPENDOPARVOVIRUS; DIAGNOSTIC IMAGING; DRUG EFFECTS; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; METABOLISM; PRIMATE; PUTAMEN; SPINAL CORD; THERAPEUTIC USE;

ANIMALS; BRAIN; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; NEURONS; PRIMATES; PUTAMEN; SPINAL CORD;

EID: 85015670634     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2017.14     Document Type: Article

References (40)

1. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convectionenhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994; 91: 2076-2080.
2. Richardson RM, Kells AP, Rosenbluth KH, Salegio EA, Fiandaca MS, Larson PS, et al. Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther 2011; 19: 1048-1057.
3. Richardson RM, Kells AP, Martin AJ, Larson PS, Starr PA, Piferi PG, et al. Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact Funct Neurosurg 2011; 89: 141-151.
4. Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS. Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 2008; 5: 123-127.
5. Fiandaca MS, Varenika V, Eberling J, McKnight T, Bringas J, Pivirotto P, et al. Realtime MR imaging of adeno-Associated viral vector delivery to the primate brain. NeuroImage 2009; 47: T27-T35.
6. Salegio EA, Samaranch L, Kells AP, Mittermeyer G, San Sebastian W, Zhou S, et al. Axonal transport of adeno-Associated viral vectors is serotype-dependent. Gene Ther 2013; 20: 348-352.
7. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009; 27: 59-65.
8. Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 2011; 19: 1058-1069.
9. Samaranch L, Salegio EA, San Sebastian W, Kells AP, Foust KD, Bringas JR, et al. Adeno-Associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther 2012; 23: 382-389.
10. Samaranch L, Salegio EA, San Sebastian W, Kells AP, Bringas JR, Forsayeth J, et al. Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther 2013; 24: 526-532.
11. Ciesielska A, Hadaczek P, Mittermeyer G, Zhou S, Wright JF, Bankiewicz KS, et al. Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cellmediated immune responses. Mol Ther 2013; 21: 158-166.
12. Samaranch L, San Sebastian W, Kells AP, Salegio EA, Heller G, Bringas JR, et al. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigenpresenting cell transduction. Mol Ther 2014; 22: 329-337.
13. Kells AP, Hadaczek P, Yin D, Bringas J, Varenika V, Forsayeth J, et al. Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci USA 2009; 106: 2407-2411.
14. Kells AP, Forsayeth J, Bankiewicz KS. Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain. Neurobiol Dis 2012; 48: 228-235.
15. Ciesielska A, Mittermeyer G, Hadaczek P, Kells AP, Forsayeth J, Bankiewicz KS. Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther 2011; 19: 922-927.
16. Thorne BA, Takeya RK, Peluso RW. Manufacturing recombinant adeno-Associated viral vectors from producer cell clones. Hum Gene Ther 2009; 20: 707-714.
17. Martin J, Frederick A, Luo Y, Jackson R, Joubert M, Sol B, et al. Generation and characterization of adeno-Associated virus producer cell lines for research and preclinical vector production. Hum Gene Ther Methods 2013; 24: 253-269.
18. Hadaczek P, Stanek L, Ciesielska A, Sudhakar V, Samaranch L, Pivirotto P, et al. Widespread AAV1- And AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's disease. Mol Ther Methods Clin Dev 2016; 3: 16037.
19. Dong B, Duan X, Chow HY, Chen L, Lu H, Wu W, et al. Proteomics analysis of copurifying cellular proteins associated with rAAV vectors. PLoS One 2014; 9: e86453.
20. San Sebastian W, Samaranch L, Heller G, Kells AP, Bringas J, Pivirotto P, et al. Adeno-Associated virus type 6 is retrogradely transported in the non-human primate brain. Gene Ther 2013; 20: 1178-1183.
21. Green F, Samaranch L, Zhang HS, Manning-Bog A, Meyer K, Forsayeth J, et al. Axonal transport of AAV9 in nonhuman primate brain. Gene Ther 2016; 23: 520-526.
22. Matsuzaki Y, Konno A, Mukai R, Honda F, Hirato M, Yoshimoto Y, et al. Transduction profile of the marmoset central nervous system using adenoassociated virus serotype 9 vectors. Mol Neurobiol 2016; doi: 10.1007/s12035-016-9777-6.
23. Castle MJ, Perlson E, Holzbaur EL, Wolfe JH. Long-distance axonal transport of AAV9 is driven by dynein and kinesin-2 and is trafficked in a highly motile Rab7-positive compartment. Mol Ther 2014; 22: 554-566.
24. Cressant A, Desmaris N, Vérot L, Bréjot T, Froissart R, Vanier M-T, et al. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-Associated virus-mediated gene transfer in the striatum. J Neurosci 2004; 24: 10229-10239.
25. Ellinwood NM, Ausseil J, Desmaris N, Bigou S, Liu S, Jens JK, et al. Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther 2011; 19: 251-259.
26. Keiser MS, Boudreau RL, Davidson BL. Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy. Mol Ther 2013; 22: 588-595.
27. Zabner J, Seiler M, Walters R, Kotin RM, Fulgeras W, Davidson BL, et al. Adenoassociated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000; 74: 3852-3858.
28. Rayaprolu V, Kruse S, Kant R, Venkatakrishnan B, Movahed N, Brooke D, et al. Comparative analysis of adeno-Associated virus capsid stability and dynamics. J Virol 2013; 87: 13150-13160.
29. Emborg ME, Hurley SA, Joers V, Tromp DPM, Swanson CR, Ohshima-Hosoyama S, et al. Titer and product affect the distribution of gene expression after intraputaminal convection-enhanced delivery. Stereotact Funct Neurosurg 2014; 92: 182-194.
30. Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA, et al. Recombinant adeno-Associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci 2000; 97: 3428-3432.
31. Nanou A, Higginbottom A, Valori CF, Wyles M, Ning K, Shaw P, et al. Viral delivery of antioxidant genes as a therapeutic strategy in experimental models of amyotrophic lateral sclerosis. Mol Ther 2013; 21: 1486-1496.
32. Merienne N, Douce JL, Faivre E, Déglon N, Bonvento G. Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors. Front Cell Neurosci 2013; 7: 106.
33. Jakobsson J, Lundberg C. Lentiviral vectors for use in the central nervous system. Mol Ther 2006; 13: 484-493.
34. Forsayeth J, Bankiewicz KS. Transduction of antigen-presenting cells in the brain by AAV9 warrants caution in preclinical studies. Mol Ther 2015; 23: 612.
35. San Sebastian W, Kells AP, Bringas J, Samaranch L, Hadaczek P, Ciesielska A, et al. Safety and tolerability of MRI-guided infusion of AAV2-hAADC into the mid-brain of non-human primates. Mol Ther Methods Clin Dev 2014; 3. doi: 10.1038/mtm.2014.49.
36. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-Associated virus type 2 vectors. Hum Gene Ther 2002; 13: 1935-1943.
37. Unzu C, Hervás-Stubbs S, Sampedro A, Mauleón I, Mancheño U, Alfaro C, et al. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J Transl Med 2012; 10: 122.
38. Salegio EA, Bringas J, Bankiewicz KS. MRI-guided delivery of viral vectors. Methods Mol Biol 2016; 1382: 217-230.
39. Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using prodrug approach. Exp Neurol 2000; 164: 2-14.
40. Krauze MT, Saito R, Noble C, Tamas M, Bringas J, Park JW, et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 2005; 103: 923-929.